Aquestive reports study results for Anaphylm ahead of NDA resubmission
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film
August 10, 2026 7:00 AM EDTHuman factors and clinical study results support planned resubmission of Anaphylm NDA in the third quarter of 2026Self-administration pharmacokinetic (PK) results were comparable to clinician-administered PK resultsRevised packaging design reduced median time to open pouch from 17 seconds in the previous human factors study to 3 secondsRevised instructions for use reduced incorrect film placement from previous human factors validation study by over 80%... More
